Share on StockTwits

Illumina (NASDAQ:ILMN) Director Daniel Bradbury sold 2,100 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $172.24, for a total transaction of $361,704.00. Following the sale, the director now directly owns 12,466 shares in the company, valued at approximately $2,147,144. The sale was disclosed in a filing with the SEC, which is available at this link.

Shares of Illumina (NASDAQ:ILMN) traded up 3.44% during mid-day trading on Monday, hitting $177.91. The stock had a trading volume of 1,055,954 shares. Illumina has a 52 week low of $72.77 and a 52 week high of $185.00. The stock’s 50-day moving average is $169.5 and its 200-day moving average is $161.0. The company has a market cap of $24.800 billion and a P/E ratio of 114.90.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Wednesday, July 23rd. The company reported $0.57 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.50 by $0.07. The company had revenue of $448.00 million for the quarter, compared to the consensus estimate of $426.50 million. During the same quarter in the prior year, the company posted $0.43 earnings per share. The company’s quarterly revenue was up 29.5% on a year-over-year basis. Analysts expect that Illumina will post $2.29 EPS for the current fiscal year.

ILMN has been the subject of a number of recent research reports. Analysts at Wedbush upgraded shares of Illumina from a “neutral” rating to an “outperform” rating in a research note on Wednesday, August 20th. They now have a $200.00 price target on the stock, up previously from $165.00. Separately, analysts at Stifel Nicolaus initiated coverage on shares of Illumina in a research note on Monday, August 11th. They set a “buy” rating and a $200.00 price target on the stock. Finally, analysts at Goldman Sachs raised their price target on shares of Illumina from $184.00 to $187.00 in a research note on Tuesday, August 5th. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Illumina presently has an average rating of “Buy” and an average target price of $178.92.

Illumina, Inc (NASDAQ:ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.

Receive News & Ratings for Illumina Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.